Update on Hormonal Therapy in Hidradenitis Suppurativa.
Document Type
Article
Publication Date
4-1-2023
Publication Title
Journal of Drugs in Dermatology : JDD
Abstract
Hidradenitis suppurativa (HS), a chronic inflammatory disorder of the apocrine-bearing skin, presents with deep seated inflamed nodules, abscesses, draining sinus tracts, and scarring with a profound impact on quality of life. In this review of Pubmed, EMBASE, and Cochrane Central databases, we focus on the role of hormonal therapies in the treatment of HS, including finasteride, cyproterone acetate, spironolactone, oral contraceptive pills, and metformin. A detailed search was conducted on these databases using key words like ‘hidradenitis suppurativa’, ‘acne inversa’, ‘antiandrogens’, and ‘hormonal therapy’. J Drugs Dermatol. 2023;22(4): doi:10.36849/JDD.6235 Citation: Karagaiah P, Daveluy S, Ortega Loayza A, et al. Update on hormonal therapy in hidradenitis suppurativa. J Drugs Dermatol. 2023;22(4):369-374. doi:10.36849/JDD.6235.
Volume
22
Issue
4
First Page
369
Last Page
374
Recommended Citation
Karagaiah P, Daveluy S, Ortega-Loayza A, Gulliver W, Szepietowski J, Grabbe S, et al. Update on hormonal therapy in hidradenitis suppurativa. J Drugs Dermatol. 2023 Apr 1;22(4):369-374. doi: 10.36849/JDD.6235. PMID: 37026880.
DOI
10.36849/JDD.6235
ISSN
1545-9616
PubMed ID
37026880